Dan Su

机构：University of Science and Technology of China, First Affiliated Hospital of Henan University of Science and Technology, Affiliated Hospital of Hebei University · ORCID：0000-0002-8423-1994

发表论文 209 篇 · 总被引 5032 次 · h-index 40

代表论文

• Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis (2025 · Annals of Medicine · 被引 12)
• Low molecular weight heparin dosing regimens after total joint arthroplasty: a prospective, single-center, randomized, double-blind study (2024 · Journal of Orthopaedic Surgery and Research · 被引 10)
• Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe (2024 · International Journal of Clinical Pharmacy · 被引 9)
• FluoBase: a fluorinated agents database (2025 · Journal of Cheminformatics · 被引 6)
• Exploring palliative care needs of advanced AIDS patients in China: insights from a descriptive phenomenological study (2025 · BMC Palliative Care · 被引 4)
• Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway (2025 · Discover Oncology · 被引 1)